526 organization(s) found
IC–OS (International Cardio–Oncology Society)
The International Cardio-Oncology Society is committed to raising awareness about cardiovascular disease that commonly occurs in patients undergoing treatment for cancer. The ongoing success and complexity of current life-saving therapies has led to the recognition by healthcare providers, patients, and caregivers that cardiac health is vitally important in order to obtain the best patient outcomes. We aim to enhance recognition among providers that prevention and early detection of cardiovascular disease is essential to providing optimal protection for our patients.
IEO (European Institute of Oncology)
The IEO (European Institute of Oncology) is one of the world's most prestigious hospitals and the fastest growing comprehensive cancer centre in Europe. IEO integrates the various areas related to the fight against cancer such as prevention, diagnosis, treatment, training and education, basic and translational research. Mission & Values: The European Institute of Oncology (Istituto Europeo di Oncologia - IEO) strives for excellence in cancer prevention, early diagnosis and effective treatment. We aim to achieve this through clinical and scientific research development, organisational and management innovation, with a constant focus on the quality of the service provided to the patients.
INCa
In French: "L’Institut national du cancer (INCa) a pour ambition de jouer un rôle d’accélérateur de progrès, en apportant une vision intégrée de l’ensemble des dimensions sanitaire, scientifique, sociale, économique liées aux pathologies cancéreuses ainsi que des différents champs d’intervention (prévention, dépistage, soins, recherche). Ceci, au service des personnes malades, de leurs proches, des usagers du système de santé, de la population générale, des professionnels de santé, des chercheurs et des décideurs."
INCA (Instituto Nacional de Câncer)
INCA is the body of the Ministry of Health responsible for the development and coordination of integrated actions in the prevention and control of cancer in Brazil. Those actions include hospital care provided directly and free of charge to cancer patients within Brazil's Unified Public Health System (SUS), and interventions in other strategic areas, such as prevention and early detection, training, research and epidemiological information. The Institute coordinates several national programs on cancer control and is equipped with the most modern public diagnostic imaging facility in Latin America.
INCan (Instituto Nacional de Cancerología)
In Spanish: "El Instituto Nacional de Cancerología es un organismo descentralizado de tercer nivel, dependiente de la Secretaría de Salud; que brinda atención médica especializada a enfermos oncológicos siendo además un centro de referencia y órgano rector del cáncer en México. Dirige sus acciones a la atención de pacientes no derechohabientes de la seguridad social, provenientes de todo el país y ha sido política institucional, el otorgar servicios con eficiencia, calidad y calidez, con enfoque multidisciplinario en proceso diagnóstico, tratamiento, rehabilitación y seguimiento. Aunado a las funciones asistenciales como centro de enseñanza médica e investigación."
INC - Colombia (Instituto Nacional de Cancerología)
The National Cancer Institute (nstituto Nacional de Cancerología [INC], in Spanish) is the only State Entity at the national level, dedicated exclusively to the teaching, prevention, diagnosis, treatment, rehabilitation and intervention of cancer.
INEN (Instituto Nacional de Enfermedades Neoplásicas)
In Spanish: “MISIÓN: El Instituto Nacional de Enfermedades Neoplásicas (INEN), tiene como misión: "Proteger, promover, prevenir y garantizar la atención integral del paciente oncológico, dando prioridad a las personas de escasos recursos económicos; así como, controlar, técnica y administrativamente, a nivel nacional los servicios de salud de las enfermedades neoplásicas y realizar las actividades de investigación y docencia propias del Instituto”. VISIÓN: El Instituto Nacional de Enfermedades Neoplásicas (INEN), tiene como visión: “Perú libre de cáncer avanzado a través de nuestro liderazgo en políticas y acciones de excelencia que promuevan el acceso universal y equitativo a la prevención y control del cáncer”.”
Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: antibody Drug Conjugates (ADC), monoclonal antibodies (mAbs) and multi-specific NK Cell Engagers through its proprietary ANKET® (Antibody-based NK cell Engager Therapeutics) platform.
Institut Curie
Made up of an internationally renowned Research Center and a cutting-edge Hospital Group, Institut Curie, the first French cancer center, treats all cancers, even the most rare forms.
Institut de la Leucémie Paris Saint-Louis
In French: "L’Institut de la Leucémie est un Institut Hospitalo-Universitaire (IHU) fondé en 2023 par l’Assistance Publique–Hôpitaux de Paris, l’INSERM, le Collège de France et l’Université Paris Cité et abrité par la Fondation Université Paris Cité (FUPC). Il incarne une dynamique collaborative sans précédent, réunissant des expertises cliniques et scientifiques autour d’une ambition commune : transformer la prise en charge des patients atteints de leucémies aiguës et maladies apparentées."
Institut du Cancer Paris CARPEM
In French: "Pour une meilleure prise en charge des patients atteints de cancer, AP-HP.Centre – Université Paris Cité et le SIRIC CARPEM ont créé l’Institut du Cancer Paris CARPEM. Il réunit les activités liées à la prise en charge des patients adultes atteints de cancer de tous nos hôpitaux, et regroupe ainsi les forces du GHU AP-HP.Centre-Université Paris Cité en soins, recherche et enseignement. L’Institut est accrédité « Comprehensive Cancer Center » par l’Organisation des Instituts européens du Cancer (OECI). Cette accréditation, délivrée pour 5 ans, récompense l’engagement et l’excellence des équipes impliquées dans la prise en charge des patients atteints de cancer."
IOR
The Institute of Oncology Research (IOR), located in Bellinzona (Switzerland) and directed by Prof. Andrea Alimonti, hosts researchers from all over the world performing basic and translational research in oncology with special focus on cancer biology, genomics, molecular oncology and experimental therapeutics. The IOR is affiliated to the Università della Svizzera italiana (USI) and is located in a brand-new high-tech research building that hosts more than 20 different research groups, with state-of-the-art labs and facilities.